Compare ARK Fintech Innovation ETF (ARKF) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Fintech Innovation ETF vs Novo Nordisk A/S — how do they compare? ARK Fintech Innovation ETF trades at $41.23, while Novo Nordisk A/S trades at $49.18 (market cap $216.71B). The key difference: Novo Nordisk A/S pays a 3.64% dividend while ARK Fintech Innovation ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, ARK Fintech Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKF | NVO | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $58.82 | $71.70 |
52-Week Low | $36.14 | $35.29 |
Market Cap | — | $216.71B |
Enterprise Value | — | $235.67B |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKF trades at $41.63, up 0.43% with bullish technical signals from moving averages and strong trend strength (ADX 39.69). The stock faces resistance at $42 with support at $41. Recent coverage highlights institutional interest in Cathie Wood's and Bill Ackman's overlapping investments in Magnificent Seven stocks.
The ETF's outlook is supported by technical momentum but lacks fundamental financial data disclosure. Key risks include market volatility and dependency on top holdings performance. Institutional overlap suggests confidence in selected growth stocks, though valuation metrics remain undisclosed.
Novo Nordisk (NVO) trades at $49.48, up 1.23% today, with a bullish technical signal from moving averages and strong fundamentals including a 37.2% net income margin and 71.4% ROE. Recent earnings beats in Q3 2025-Q1 2026 highlight operational strength, while cash flow remains positive at $10.81B in 2025. The stock benefits from GLP-1 drug leadership, with oral Wegovy driving market expansion amid competitive pressures.
Outlook is positive with analyst consensus at 57.9% buy ratings, but risks include prescription slowdown concerns and rising debt-to-asset ratio to 22.54 in 2025. Investment appeal lies in robust profitability and growth in obesity/diabetes treatments, though investors should monitor competition and execution on guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Fintech Innovation ETF
ARKF is an actively managed ETF that invests in companies leading the way in fintech innovation. Key themes include mobile payments, digital wallets, blockchain technology, and frictionless funding platforms.
Read more on ARKF →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
